Vasanthavada Madhav 4

What Happened

• Vasanthavada Madhav, Chief Commercial Officer of Abeona Therapeutics (ABEO), sold a total of 9,620 shares in open-market transactions on June 8–9, 2026. The filings report proceeds of about $22,641 on 2026-06-08 (4,170 shares at a weighted average ~$5.43) and $28,908 on 2026-06-09 (5,450 shares at a weighted average ~$5.30), totaling roughly $51,549. These were sales rather than purchases and, per the filing, were undertaken to cover tax obligations related to the vesting of restricted stock awards (a routine/withholding transaction).

Key Details

• Transaction dates and amounts:
  • 2026-06-08: 4,170 shares sold, weighted-average price reported ~$5.43; proceeds reported ~$22,641. (Footnote F2: actual trade prices ranged $5.345–$5.54.)
  • 2026-06-09: 5,450 shares sold, weighted-average price reported ~$5.30; proceeds reported ~$28,908. (Footnote F3: actual trade prices ranged $5.24–$5.47.)
• Total shares sold: 9,620; total reported proceeds: ~ $51,549.
• Shares owned after transaction: Not specified in the provided filing.
• Notable footnotes: F1 states the sales were to cover tax withholding on vested restricted stock awards. F2/F3 note the reported prices are weighted averages with a per-trade price range; the reporter will provide per-price details on request.
• Timeliness: Report filed 2026-06-09 for transactions on 2026-06-08 and 2026-06-09 (no late filing indicated).

Context

• These sales were tax-withholding sales tied to restricted stock vesting (common and routine for executives) rather than discretionary open-market selling to take a position view. The filing’s weighted-average prices and the promise to provide per-trade breakdowns on request mean the exact per-trade prices are available from the filer or the SEC staff if needed. Sales (code S) and tax-withholding (as described in the footnote) are not the same signal as a voluntary sell intended to rebalance or exit a position.